FMP
Fennec Pharmaceuticals Inc.
FENC
NASDAQ
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
6.19 USD
-0.02 (-0.323%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Rostislav Raykov
sector
Healthcare
industry
Biotechnology
website
https://www.fennecpharma.comexchange
NASDAQ
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
CIK
0001211583
ISIN
CA31447P1009
CUSIP
31447P100
Address
68 TW Alexander Drive
Phone
919 636 4530
Country
US
Employee
29
IPO Date
Sep 15, 2017
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
FENC Financial Summary
CIK
0001211583
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
31447P100
ISIN
CA31447P1009
Country
US
Price
6.19
Beta
0.27
Volume Avg.
119.68k
Market Cap
169.78M
Shares
-
52-Week
3.96-11.92
DCF
-3.33
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-154.75
P/B
-
Website
https://www.fennecpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest FENC News
It looks like there's no news available.
